{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:58:59Z","timestamp":1785441539738,"version":"3.56.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"DOI":"10.1007\/s00702-026-03244-7","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:38:32Z","timestamp":1785393512000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of botulinum toxin in the multimodal management of pain in Parkinson\u2019s disease: a scoping review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7682-1353","authenticated-orcid":false,"given":"Bo","family":"Biering-S\u00f8rensen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Wissel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Gurevich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Kaelin-Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor N.","family":"Petrovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zvezdan","family":"Pirto\u0161ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladana","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Rudzi\u0144ska-Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Milanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"3244_CR1","doi-asserted-by":"publisher","first-page":"1248828","DOI":"10.3389\/fneur.2023.1248828","volume":"14","author":"P Alizadeh","year":"2023","unstructured":"Alizadeh P, Terroba-Chambi C, Achen B et al (2023) Pain in monogenic Parkinson\u2019s disease: a comprehensive review. Front Neurol 14:1248828. https:\/\/doi.org\/10.3389\/fneur.2023.1248828","journal-title":"Front Neurol"},{"issue":"Suppl 1","key":"3244_CR2","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-230227","volume":"14","author":"NE Allen","year":"2024","unstructured":"Allen NE, Romaliiska O, Naisby J (2024) Pain and the non-pharmacological management of pain in people with Parkinson\u2019s disease. J Parkinsons Dis 14(Suppl 1):S65\u2013S80. https:\/\/doi.org\/10.3233\/JPD-230227","journal-title":"J Parkinsons Dis"},{"key":"3244_CR3","doi-asserted-by":"publisher","first-page":"1371601","DOI":"10.3389\/fnins.2024.1371601","volume":"18","author":"C Anandan","year":"2024","unstructured":"Anandan C, Jankovic J (2024a) Use of botulinum toxin in the management of dystonia in Parkinson\u2019s disease. Front Neurosci 18:1371601. https:\/\/doi.org\/10.3389\/fnins.2024.1371601","journal-title":"Front Neurosci"},{"key":"3244_CR4","doi-asserted-by":"publisher","first-page":"122810","DOI":"10.1016\/j.jns.2023.122810","volume":"456","author":"C Anandan","year":"2024","unstructured":"Anandan C, Jankovic J (2024b) Botulinum toxin treatment in parkinsonism. J Neurol Sci 456:122810. https:\/\/doi.org\/10.1016\/j.jns.2023.122810","journal-title":"J Neurol Sci"},{"key":"3244_CR5","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ene.13624","volume":"25","author":"A Antonini","year":"2018","unstructured":"Antonini A, Tinazzi M, Abbruzzese G et al (2018) Pain in Parkinson\u2019s disease: facts and uncertainties. Eur J Neurol 25:917\u2013e969. https:\/\/doi.org\/10.1111\/ene.13624","journal-title":"Eur J Neurol"},{"key":"3244_CR6","doi-asserted-by":"publisher","first-page":"1240379","DOI":"10.3389\/fpain.2023.1240379","volume":"4","author":"A Askari","year":"2023","unstructured":"Askari A, Lam JLW, Zhu BJ, Lu CW, Chou KL, Wyant KJ, Patil PG (2023) Dorsal subthalamic deep brain stimulation improves pain in Parkinson\u2019s disease. Front Pain Res 4:1240379. https:\/\/doi.org\/10.3389\/fpain.2023.1240379","journal-title":"Front Pain Res"},{"key":"3244_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.4103\/aian.AIAN_449_20","volume":"23","author":"M Behari","year":"2020","unstructured":"Behari M, Srivastava A, Achtani R, Nandal N, Dutta RB (2020) Pain assessment in Indian Parkinson\u2019s disease patients using King\u2019s Parkinson\u2019s Disease Pain Scale. Ann Indian Acad Neurol 23:774\u2013780. https:\/\/doi.org\/10.4103\/aian.AIAN_449_20","journal-title":"Ann Indian Acad Neurol"},{"key":"3244_CR8","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.pnpbp.2017.10.010","volume":"87","author":"PJ Blanchet","year":"2018","unstructured":"Blanchet PJ, Brefel-Courbon C (2018) Chronic pain and pain processing in Parkinson\u2019s disease. Prog Neuropsychopharmacol Biol Psychiatry 87:200\u2013206. https:\/\/doi.org\/10.1016\/j.pnpbp.2017.10.010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"3244_CR9","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/mds.20629","volume":"20","author":"C Brefel-Courbon","year":"2005","unstructured":"Brefel-Courbon C, Payoux P, Thalamas C, Ory F, Quelven I, Chollet F, Montastruc JL, Rascol O (2005) Effect of levodopa on pain threshold in Parkinson\u2019s disease: a clinical and positron emission tomography study. Mov Disord 20:1557\u20131563. https:\/\/doi.org\/10.1002\/mds.20629","journal-title":"Mov Disord"},{"key":"3244_CR11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1017\/cjn.2016.279","volume":"43","author":"VA Bruno","year":"2016","unstructured":"Bruno VA, Fox SH, Mancini D, Miyasaki JM (2016) Botulinum toxin use in refractory pain and other symptoms in parkinsonism. Can J Neurol Sci 43:697\u2013702. https:\/\/doi.org\/10.1017\/cjn.2016.279","journal-title":"Can J Neurol Sci"},{"key":"3244_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1017\/cjn.2017.245","volume":"45","author":"V Bruno","year":"2018","unstructured":"Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH (2018) Botulinum toxin type A for pain in advanced Parkinson\u2019s disease. Can J Neurol Sci 45:23\u201329. https:\/\/doi.org\/10.1017\/cjn.2017.245","journal-title":"Can J Neurol Sci"},{"key":"3244_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1007\/s00415-017-8426-y","volume":"264","author":"C Buhmann","year":"2017","unstructured":"Buhmann C, Wrobel N, Grashorn W, Fruendt O, Wesemann K, Diedrich S, Bingel U (2017) Pain in Parkinson disease: a cross-sectional survey of its prevalence, specifics, and therapy. J Neurol 264:758\u2013769. https:\/\/doi.org\/10.1007\/s00415-017-8426-y","journal-title":"J Neurol"},{"issue":"S1","key":"3244_CR12","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.3233\/JPD-202069","volume":"10","author":"C Buhmann","year":"2020","unstructured":"Buhmann C, Kassubek J, Jost WH (2020) Management of pain in Parkinson\u2019s disease. J Parkinsons Dis 10(S1):S37\u2013S48. https:\/\/doi.org\/10.3233\/JPD-202069","journal-title":"J Parkinsons Dis"},{"key":"3244_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/toxins18010028","volume":"18","author":"BA Chaudhry","year":"2026","unstructured":"Chaudhry BA et al (2026) Central and peripheral sensitization in temporomandibular disorders: proposed mechanisms of botulinum toxin therapy. Toxins (Basel) 18:28. https:\/\/doi.org\/10.3390\/toxins18010028","journal-title":"Toxins (Basel)"},{"key":"3244_CR15","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/mds.26270","volume":"30","author":"KR Chaudhuri","year":"2015","unstructured":"Chaudhuri KR, Rizos A, Trenkwalder C et al (2015) King\u2019s Parkinson\u2019s disease pain scale: the first scale for pain in Parkinson\u2019s disease\u2014an international validation. Mov Disord 30:1623\u20131631. https:\/\/doi.org\/10.1002\/mds.26270","journal-title":"Mov Disord"},{"key":"3244_CR16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2015.4452","volume":"73","author":"CE Clarke","year":"2016","unstructured":"Clarke CE, Patel S, Ives N et al (2016) Physiotherapy and occupational therapy vs no therapy in mild to moderate Parkinson disease: a randomized clinical trial. JAMA Neurol 73:291\u2013299. https:\/\/doi.org\/10.1001\/jamaneurol.2015.4452","journal-title":"JAMA Neurol"},{"key":"3244_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archneurol.2008.2","volume":"65","author":"G Defazio","year":"2008","unstructured":"Defazio G, Berardelli A, Fabbrini G et al (2008) Pain as a nonmotor symptom of Parkinson disease: evidence from a case-control study. Arch Neurol 65:1191\u20131194. https:\/\/doi.org\/10.1001\/archneurol.2008.2","journal-title":"Arch Neurol"},{"key":"3244_CR17","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/ene.13323","volume":"24","author":"G Defazio","year":"2017","unstructured":"Defazio G, Antonini A, Tinazzi M et al (2017) Relationship between pain and motor and non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol 24:974\u2013980. https:\/\/doi.org\/10.1111\/ene.13323","journal-title":"Eur J Neurol"},{"key":"3244_CR19","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mdc3.13754","volume":"10","author":"DG Di Luca","year":"2023","unstructured":"Di Luca DG, Gilmour GS, Fearon C et al (2023) A phase Ib, double blind, randomized study of cannabis oil for pain in Parkinson\u2019s disease. Mov Disord Clin Pract 10:1114\u20131119. https:\/\/doi.org\/10.1002\/mdc3.13754","journal-title":"Mov Disord Clin Pract"},{"key":"3244_CR20","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/medicina61040591","volume":"61","author":"S Diaconu","year":"2025","unstructured":"Diaconu S, Ciopleias B, Zarnoveanu A, Falup-Pecurariu C (2025) Sleep disturbances and pain subtypes in Parkinson\u2019s disease. Medicina 61:591. https:\/\/doi.org\/10.3390\/medicina61040591","journal-title":"Medicina"},{"key":"3244_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.parkreldis.2017.02.007","volume":"39","author":"M Fabbri","year":"2017","unstructured":"Fabbri M, Coelho M, Guedes LC et al (2017) Response of non-motor symptoms to levodopa in late-stage Parkinson\u2019s disease: results of a levodopa challenge test. Parkinsonism Relat Disord 39:37\u201343. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.02.007","journal-title":"Parkinsonism Relat Disord"},{"key":"3244_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s00415-024-12730-5","volume":"272","author":"A Fanciulli","year":"2025","unstructured":"Fanciulli A, Sixel-D\u00f6ring F, Buhmann C et al (2025) Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson\u2019s disease: guideline Parkinson\u2019s disease of the German Society of Neurology. J Neurol 272:90. https:\/\/doi.org\/10.1007\/s00415-024-12730-5","journal-title":"J Neurol"},{"key":"3244_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40478-021-01131-8","volume":"9","author":"N Ferreira","year":"2021","unstructured":"Ferreira N, Gon\u00e7alves NP, Jan A, Jensen NM, van der Laan A, Mohseni S, V\u00e6gter CB, Jensen PH (2021) Trans-synaptic spreading of alpha-synuclein pathology through sensory afferents leads to sensory nerve degeneration and neuropathic pain. Acta Neuropathol Commun 9:31. https:\/\/doi.org\/10.1186\/s40478-021-01131-8","journal-title":"Acta Neuropathol Commun"},{"issue":"S1","key":"3244_CR24","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1002\/mds.22716","volume":"25","author":"B Ford","year":"2010","unstructured":"Ford B (2010) Pain in Parkinson\u2019s disease. Mov Disord 25(S1):S98\u2013S103. https:\/\/doi.org\/10.1002\/mds.22716","journal-title":"Mov Disord"},{"key":"3244_CR25","doi-asserted-by":"publisher","first-page":"7503190030","DOI":"10.5014\/ajot.2021.046581","volume":"75","author":"ER Foster","year":"2021","unstructured":"Foster ER, Carson LG, Archer J, Hunter EG (2021) Occupational therapy interventions for instrumental activities of daily living for adults with Parkinson\u2019s disease: a systematic review. Am J Occup Ther 75:7503190030. https:\/\/doi.org\/10.5014\/ajot.2021.046581","journal-title":"Am J Occup Ther"},{"key":"3244_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1136\/jnnp.53.2.96","volume":"53","author":"JP Frankel","year":"1990","unstructured":"Frankel JP, Lees AJ, Kempster PA, Stern GM (1990) Subcutaneous apomorphine in the treatment of Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 53:96\u2013101. https:\/\/doi.org\/10.1136\/jnnp.53.2.96","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3244_CR27","doi-asserted-by":"publisher","first-page":"559348","DOI":"10.2147\/JPR.S559348","volume":"19","author":"L Gao","year":"2026","unstructured":"Gao L, Li Z, Cai L, Xu W, Liu Y (2026) Association between pain subtypes and cognitive impairment in Parkinson\u2019s disease. J Pain Res 19:559348. https:\/\/doi.org\/10.2147\/JPR.S559348","journal-title":"J Pain Res"},{"key":"3244_CR28","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.3390\/jpm11080798","volume":"10","author":"DS Garc\u00eda","year":"2021","unstructured":"Garc\u00eda DS, Labandeira C, P\u00e9rez-Fern\u00e1ndez S et al (2021) Pain improvement in Parkinson\u2019s disease patients treated with safinamide: results from the SAFINONMOTOR study. J Clin Med 10:4060. https:\/\/doi.org\/10.3390\/jpm11080798","journal-title":"J Clin Med"},{"key":"3244_CR29","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1136\/jnnp.2007.120212","volume":"78","author":"A Gerdelat-Mas","year":"2007","unstructured":"Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C et al (2007) Levodopa raises objective pain threshold in Parkinson\u2019s disease: a RIII reflex study. J Neurol Neurosurg Psychiatry 78:1140\u20131142. https:\/\/doi.org\/10.1136\/jnnp.2007.120212","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3244_CR30","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.26355\/eurrev_202107_26394","volume":"25","author":"S Giovannini","year":"2021","unstructured":"Giovannini S, Laudisio A, Navarini L et al (2021) Polypharmacy is a determinant of hospitalization in Parkinson\u2019s disease. Eur Rev Med Pharmacol Sci 25:4810\u20134817. https:\/\/doi.org\/10.26355\/eurrev_202107_26394","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3244_CR31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.5114\/hm.2023.130100","volume":"24","author":"TT Henemann","year":"2023","unstructured":"Henemann TT, Truchem L, Siega J, Paladini LH, Israel VL (2023) Physical therapy interventions to manage pain in Parkinson\u2019s disease: a systematic review. Hum Mov 24:31\u201343. https:\/\/doi.org\/10.5114\/hm.2023.130100","journal-title":"Hum Mov"},{"key":"3244_CR32","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1002\/mds.22596","volume":"24","author":"H Honig","year":"2009","unstructured":"Honig H, Antonini A, Martinez-Martin P et al (2009) Intrajejunal levodopa infusion in Parkinson\u2019s disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 24:1468\u20131474. https:\/\/doi.org\/10.1002\/mds.22596","journal-title":"Mov Disord"},{"key":"3244_CR33","doi-asserted-by":"publisher","first-page":"116833","DOI":"10.1016\/j.jns.2020.116833","volume":"414","author":"H Iwaki","year":"2020","unstructured":"Iwaki H, Ando R, Tada S et al (2020) A double-blind, randomized controlled trial of duloxetine for pain in Parkinson\u2019s disease. J Neurol Sci 414:116833. https:\/\/doi.org\/10.1016\/j.jns.2020.116833","journal-title":"J Neurol Sci"},{"key":"3244_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3390\/toxins15020081","volume":"15","author":"B Jabbari","year":"2023","unstructured":"Jabbari B, Comtesse SM (2023) Botulinum toxin treatment of motor disorders in Parkinson disease-a systematic review. Toxins (Basel) 15:81. https:\/\/doi.org\/10.3390\/toxins15020081","journal-title":"Toxins (Basel)"},{"key":"3244_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00702-024-02805-y","volume":"131","author":"WH Jost","year":"2024","unstructured":"Jost WH, Berberovic E (2024) Therapy with botulinum neurotoxin for Parkinson\u2019s disease. J Neural Transm (Vienna) 131:1321\u20131328. https:\/\/doi.org\/10.1007\/s00702-024-02805-y","journal-title":"J Neural Transm (Vienna)"},{"key":"3244_CR36","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1471-2377-14-42","volume":"14","author":"J Kassubek","year":"2014","unstructured":"Kassubek J et al (2014) Rotigotine transdermal system and evaluation of pain in patients with Parkinson\u2019s disease: a post hoc analysis of the RECOVER study. BMC Neurol 14:42. https:\/\/doi.org\/10.1186\/1471-2377-14-42","journal-title":"BMC Neurol"},{"key":"3244_CR38","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00415-009-0908-0","volume":"255","author":"HJ Kim","year":"2008","unstructured":"Kim HJ, Paek SH, Kim JY et al (2008) Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol 255:1889\u20131894. https:\/\/doi.org\/10.1007\/s00415-009-0908-0","journal-title":"J Neurol"},{"key":"3244_CR37","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.3390\/toxins7072435","volume":"7","author":"DW Kim","year":"2015","unstructured":"Kim DW, Lee SK, Ahnn J (2015) Botulinum toxin as a pain killer: players and actions in antinociception. Toxins (Basel) 7:2435\u20132453. https:\/\/doi.org\/10.3390\/toxins7072435","journal-title":"Toxins (Basel)"},{"key":"3244_CR39","doi-asserted-by":"publisher","first-page":"e074372","DOI":"10.1136\/bmjopen-2023-074372","volume":"14","author":"M Klee","year":"2024","unstructured":"Klee M, H\u00f8rmann Thomsen T, Enggaard TP, Bitsch MS, Simonsen L, Jensen RH, Biering-S\u00f8rensen B (2024) Perineural injections of incobotulinumtoxin-A for diabetic neuropathic pain of the lower extremities: protocol for a phase II, single-centre, double-blind, randomised, placebo-controlled trial (the PINBOT study). BMJ Open 14:e074372. https:\/\/doi.org\/10.1136\/bmjopen-2023-074372","journal-title":"BMJ Open"},{"key":"3244_CR40","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/mds.23048","volume":"25","author":"MB Madden","year":"2010","unstructured":"Madden MB, Hall DA (2010) Shoulder pain in Parkinson\u2019s disease: a case-control study. Mov Disord 25:1105\u20131106. https:\/\/doi.org\/10.1002\/mds.23048","journal-title":"Mov Disord"},{"key":"3244_CR42","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/j.pain.0000000000002107","volume":"162","author":"V Mylius","year":"2021","unstructured":"Mylius V, Perez Lloret S, Cury RG et al (2021a) The Parkinson disease pain classification system: results from an international mechanism-based classification approach. Pain 162:1201\u20131210. https:\/\/doi.org\/10.1097\/j.pain.0000000000002107","journal-title":"Pain"},{"key":"3244_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40266-021-00867-1","volume":"38","author":"V Mylius","year":"2021","unstructured":"Mylius V, M\u00f6ller JC, Bohlhalter S, Ciampi de Andrade D, Perez Lloret S (2021b) Diagnosis and management of pain in Parkinson\u2019s disease: a new approach. Drugs Aging 38:559\u2013577. https:\/\/doi.org\/10.1007\/s40266-021-00867-1","journal-title":"Drugs Aging"},{"key":"3244_CR44","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1007\/s00415-021-10586-7","volume":"268","author":"J Naisby","year":"2021","unstructured":"Naisby J, Lawson RA, Galna B, Alcock L, Burn DJ, Rochester L, Yarnall AJ (2021) Trajectories of pain over 6 years in early Parkinson\u2019s disease: ICICLE-PD. J Neurol 268:4759\u20134767. https:\/\/doi.org\/10.1007\/s00415-021-10586-7","journal-title":"J Neurol"},{"key":"3244_CR43","doi-asserted-by":"publisher","first-page":"fcae210","DOI":"10.1093\/braincomms\/fcae210","volume":"6","author":"D Nardelli","year":"2024","unstructured":"Nardelli D, Gambioli F, De Bartolo MI et al (2024) Pain in Parkinson\u2019s disease: a neuroanatomy-based approach. Brain Commun 6:fcae210. https:\/\/doi.org\/10.1093\/braincomms\/fcae210","journal-title":"Brain Commun"},{"key":"3244_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/mds.21813","volume":"23","author":"SS O\u2019Sullivan","year":"2008","unstructured":"O\u2019Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson\u2019s disease: a clinicopathological study. Mov Disord 23:101\u2013106. https:\/\/doi.org\/10.1002\/mds.21813","journal-title":"Mov Disord"},{"key":"3244_CR45","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/acn3.70174","volume":"12","author":"NS Ogonowski","year":"2025","unstructured":"Ogonowski NS, Chafota F, Cao F et al (2025) Chronic pain in Parkinson\u2019s disease: prevalence, sex differences, regional anatomy and comorbidities. Ann Clin Transl Neurol 12:2422\u20132432. https:\/\/doi.org\/10.1002\/acn3.70174","journal-title":"Ann Clin Transl Neurol"},{"key":"3244_CR46","doi-asserted-by":"publisher","first-page":"3127","DOI":"10.3390\/toxins7083127","volume":"7","author":"HM Oh","year":"2015","unstructured":"Oh HM, Chung ME (2015) Botulinum toxin for neuropathic pain: a review of the literature. Toxins (Basel) 7:3127\u20133154. https:\/\/doi.org\/10.3390\/toxins7083127","journal-title":"Toxins (Basel)"},{"key":"3244_CR48","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1016\/s0140-6736(86)91674-0","volume":"1","author":"NP Quinn","year":"1986","unstructured":"Quinn NP, Koller WC, Lang AE, Marsden CD (1986) Painful Parkinson\u2019s disease. Lancet 1:1366\u20131369. https:\/\/doi.org\/10.1016\/s0140-6736(86)91674-0","journal-title":"Lancet"},{"key":"3244_CR49","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/jcph.678","volume":"56","author":"O Rascol","year":"2016","unstructured":"Rascol O, Zesiewicz T, Chaudhuri KR et al (2016) A randomized controlled exploratory pilot study to evaluate the effect of rotigotine transdermal patch on Parkinson\u2019s disease-associated chronic pain. J Clin Pharmacol 56:852\u2013861. https:\/\/doi.org\/10.1002\/jcph.678","journal-title":"J Clin Pharmacol"},{"key":"3244_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.parkreldis.2017.10.009","volume":"46","author":"I Rieu","year":"2018","unstructured":"Rieu I, Degos B, Castelnovo G et al (2018) Incobotulinum toxin A in Parkinson\u2019s disease with foot dystonia: a double blind randomized trial. Parkinsonism Relat Disord 46:9\u201315. https:\/\/doi.org\/10.1016\/j.parkreldis.2017.10.009","journal-title":"Parkinsonism Relat Disord"},{"key":"3244_CR51","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1600-0404.2008.01114.x","volume":"119","author":"JH Roh","year":"2009","unstructured":"Roh JH, Kim BJ, Jang JH et al (2009) The relationship of pain and health-related quality of life in Korean patients with Parkinson\u2019s disease. Acta Neurol Scand 119:397\u2013403. https:\/\/doi.org\/10.1111\/j.1600-0404.2008.01114.x","journal-title":"Acta Neurol Scand"},{"key":"3244_CR52","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/WCO.0000000000000711","volume":"32","author":"K Rukavina","year":"2019","unstructured":"Rukavina K, Leta V, Sportelli C et al (2019) Pain in Parkinson\u2019s disease. Curr Opin Neurol 32:579\u2013588. https:\/\/doi.org\/10.1097\/WCO.0000000000000711","journal-title":"Curr Opin Neurol"},{"key":"3244_CR53","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.parkreldis.2018.06.001","volume":"56","author":"MA Silverdale","year":"2018","unstructured":"Silverdale MA, Kobylecki C, Kass-Iliyya L et al (2018) A detailed clinical study of pain in 1957 participants with early\/moderate Parkinson\u2019s disease. Parkinsonism Relat Disord 56:27\u201332. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.06.001","journal-title":"Parkinsonism Relat Disord"},{"key":"3244_CR54","doi-asserted-by":"publisher","first-page":"e53309","DOI":"10.7759\/cureus.53309","volume":"16","author":"E Slouha","year":"2024","unstructured":"Slouha E, Ibrahim F, Esposito S et al (2024) Botulinum toxin for the management of Parkinson\u2019s disease: a systematic review. Cureus 16:e53309. https:\/\/doi.org\/10.7759\/cureus.53309","journal-title":"Cureus"},{"key":"3244_CR55","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/s1474-4422(25)00068-7","volume":"24","author":"N Soliman","year":"2025","unstructured":"Soliman N, Moisset X, Ferraro M et al (2025) Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurol 24:413\u2013428. https:\/\/doi.org\/10.1016\/s1474-4422(25)00068-7","journal-title":"Lancet Neurol"},{"key":"3244_CR56","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3233\/JPD-240026","volume":"14","author":"A Storch","year":"2024","unstructured":"Storch A, Bremer A, Gandor F, Odin P, Ebersbach G, L\u00f6hle M (2024) Pain fluctuations in Parkinson\u2019s disease and their association with motor and non-motor fluctuations. J Parkinsons Dis 14:1451\u20131468. https:\/\/doi.org\/10.3233\/JPD-240026","journal-title":"J Parkinsons Dis"},{"key":"3244_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.prdoa.2019.11.004","volume":"2","author":"YC Tai","year":"2019","unstructured":"Tai YC, Lin CH (2019) An overview of pain in Parkinson\u2019s disease. Clin Park Relat Disord 2:1\u20138. https:\/\/doi.org\/10.1016\/j.prdoa.2019.11.004","journal-title":"Clin Park Relat Disord"},{"key":"3244_CR58","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1136\/jnnp.2005.079053","volume":"77","author":"M Tinazzi","year":"2006","unstructured":"Tinazzi M, Del Vesco C, Fincati E et al (2006) Pain and motor complications in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 77:822\u2013825. https:\/\/doi.org\/10.1136\/jnnp.2005.079053","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"3244_CR59","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1474-4422(25)00033-X","volume":"24","author":"M Tinazzi","year":"2025","unstructured":"Tinazzi M, Gandolfi M, Artusi CA et al (2025) Advances in diagnosis, classification, and management of pain in Parkinson\u2019s disease. Lancet Neurol 24:331\u2013347. https:\/\/doi.org\/10.1016\/S1474-4422(25)00033-X","journal-title":"Lancet Neurol"},{"key":"3244_CR60","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/S1474-4422(15)00243-4","volume":"14","author":"C Trenkwalder","year":"2015","unstructured":"Trenkwalder C, Chaudhuri KR, Martinez-Martin P et al (2015) Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson\u2019s disease (PANDA): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 14:1184\u20131193. https:\/\/doi.org\/10.1016\/S1474-4422(15)00243-4","journal-title":"Lancet Neurol"},{"key":"3244_CR61","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2217\/nmt-2021-0011","volume":"11","author":"LE Tueth","year":"2021","unstructured":"Tueth LE, Duncan RP (2021) Musculoskeletal pain in Parkinson\u2019s disease: a narrative review. Neurodegenerative Disease Manage 11:373\u2013385. https:\/\/doi.org\/10.2217\/nmt-2021-0011","journal-title":"Neurodegenerative Disease Manage"},{"key":"3244_CR62","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/mds.30046","volume":"40","author":"F Vazirian","year":"2025","unstructured":"Vazirian F, Tian J, Alty J et al (2025) Chronic musculoskeletal pain and risk of incident Parkinson\u2019s disease: a 13-year longitudinal study. Mov Disord 40:87\u201396. https:\/\/doi.org\/10.1002\/mds.30046","journal-title":"Mov Disord"},{"key":"3244_CR63","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrneurol.2012.54","volume":"8","author":"G Wasner","year":"2012","unstructured":"Wasner G, Deuschl G (2012) Pains in Parkinson disease-many syndromes under one umbrella. Nat Rev Neurol 8:284\u2013294. https:\/\/doi.org\/10.1038\/nrneurol.2012.54","journal-title":"Nat Rev Neurol"},{"key":"3244_CR64","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1186\/s12883-024-03859-x","volume":"24","author":"X Wu","year":"2024","unstructured":"Wu X, Shi M, Lian Y et al (2024) Cognitive behavioral therapy approaches to the improvement of mental health in Parkinson\u2019s disease patients: a systematic review and meta-analysis. BMC Neurol 24:352. https:\/\/doi.org\/10.1186\/s12883-024-03859-x","journal-title":"BMC Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03244-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03244-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T19:05:27Z","timestamp":1785438327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-026-03244-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,30]]},"references-count":64,"alternative-id":["3244"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03244-7","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,30]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant conflict of interest with respect to the contents of this manuscript.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}